Dietary Magnesium : New Research.

Intro -- DIETARY MAGNESIUM: NEW RESEARCH -- DIETARY MAGNESIUM: NEW RESEARCH -- Contents -- Preface -- Short Communications Magnesium Concentration in Mononuclear Cells of COPD Patients in Stable Phase -- Abstract -- Introduction -- Materials and Methods -- Subjects -- Samples -- Methods -- Procedure for Spirometry -- Statistical Methods -- Results -- Conclusion -- References -- Chapter I Magnesium Intake, the Metabolic Syndrome, and Chronic Disease: A Critical Review of Epidemiologic Studies -- Abstract -- Introduction -- Magnesium Intake and Metabolic Syndrome Components -- Abdominal Obesity and Insulin Resistance -- Dyslipidemia -- Hypertension -- Systemic Inflammation and Endothelial Dysfunction -- The Metabolic Syndrome -- Magnesium Intake and Chronic Diseases -- Type 2 Diabetes Mellitus (DM) -- Cardiovascular Disease -- Colorectal Cancer -- Conclusion -- Refereces -- Chapter II Chronopathological Forms of Asthma due to Magnesium Depletion with Hypo- or Hyper-Function of the Biological Clock: Therapeutic Implications -- Abstract -- Main Abbreviations -- Introduction -- I. Magnesium Deficit in Asthma -- I.1. Hypomagnesemia in Asthma -- I.2. Other Magnesium Disturbances in Asthma -- I.3. The Two Forms of Magnesium Deficits in Asthma -- 1.3.1. Magnesium Deficiency -- 1.3.2. Magnesium depletion -- I.4. Links between Magnesium Status and Chronobiology -- II. Chronopathological Forms of Asthma -- II.1. Hyperfunction of the Biological Clock (HBC) in Asthma -- II.1.1. Clinical Form of Asthma with HBC: Nocturnal Asthma -- II.1.2. Characteristics of HBC in Asthma -- II.1.2.1. Biological Characteristic (increase in the Melatonin) -- II.1.2.2. The Clinical Forms of Neurohypoexcitability (NhE) Resulting from HBC are Both Central and Peripheral -- II.1.2.2.1. The Central Forms Associate Psychic, Algic and Hypnic Manifestations:.

II.1.2.2.2. The Peripheral Manifestations are Neuromuscular, Mainly Represented by Myalgia and Muscular Asthenia -- II.2. Hypofunction of the Biological Clock in Asthma -- II.2.1. Clinical Form of Asthma With hBC -- II.2.2. Characteristics of hBC in Asthma -- II.2.2.1. Biological Characteristic -- II.2.2. 2. Clinical Characteristics -- II.2.2.2.1. The Central Forms Associate Psychic, Algic and Hypnic Manifestations -- II.2.2.2.2. Peripheral Manifestations -- II.2.3. Indirect Evidences Suggesting the Possible Role of HBC in Asthma -- III. Treatment of Asthma with Dysfunctions of BC -- III.1. Conventional Pharmacological Treatment -- III.1.1.General Considerations -- III.1.2. Beta-2 Agonists -- III.1.2.1. Nature and Action of Beta-2 Adrenergic Receptors -- III.1.2. 2. Beta-2 Agonists and Obstructive Disorders -- III.1.2. 3. Side Effects of Beta-2 Agonists -- III.2. Indirect Asthma Therapies -- III.2.1. Environmental Control Measures -- III.2.2. All the Pathological Entities Accompanying Asthma Should be Diagnosed and Treated Appropriately [318] -- III.2.3. Asthma Education Programs -- III.2.4. Herbal Medicine -- III.2.5. Needle Acupuncture -- III.2.6. Homeopathic Remedies -- III.2.7. Diet Is Important. -- III.3. Balanced Magnesium Intake -- III.4. Chronobiological Treatments -- III.4.1. Asthma with HBC -- III.4.1.1. Bright Light Phototherapy -- III.4.1.2. Chromatotherapy -- III.4.1.3. Low Power Laser Biostimulation -- III.4.1.4. Pharmacotherapy of the Clinical Manifestations of HBC -- III.4.2. Asthma with hBC -- III.4.2.1. Stimulating "Darkness Therapies": -- III.4.2.1.1. Physiological Darkness Therapies: -- III.4.2.1.1.1. Darkness Therapy Per Se -- III.4.2.1.1.2. Chromatotherapy -- III.4.2.1.2. Psychotherapeutic Darkness Therapies -- III.4.2.1.3. Physiotherapic Darkness Therapy -- III.4.2.1.4. Pharmacological Darkness Therapy.

III.4.2.1.4.1. Magnesium Treatment for Obstructive Disorders: A Reappraisal -- III.4.2.1.4.1.1. Pharmacological Magnesium Therapy -- III.4.2.1.4.1.2. Use of Magnesium Sulfate in Acute Asthma -- A. Intravenous administration -- B. Nebulized administration -- III.4.2.1.4.1.3. Oral Administration of Magnesium in Stable Asthma -- III.4.2.1.4.2. L Tryptophan or 5-OH Tryptophan -- III.4.2.1.4.3. Taurine -- III.4.2.2. "Substitutive Darkness Therapy" or Darkness Mimicking Agents -- III.4.2.2.1. Mechanisms of the Action of Darkness -- III.4.2.2.2. Melatonin, an Accessory Darkness Mimicking Agent -- Conclusion -- References -- Chapter III Low Birth Weight and Magnesium: From the Standpoint of "Fetal Origin" Hypothesis -- Abstract -- Introduction -- Magnesium Deficiency in Pregnant Woman -- Mineral Concentration of Meconia -- Placental Transport of Magnesium -- Placental Vascular Flow and Magnesium -- Experimental Consequences of Gestational Magnesium Deficiency in Animal Studies -- Mg Supplement and Pregnancy Outcome -- Intracellular Mg in Cord Blood Platelets -- (A) Intracellular Mg and Small for Gestational Age -- (B) Correlation of [Mg2+]i and Insulin Resistance -- Fetal / Early Childhood Antecedents and Adult Chronic Diseases -- (A) Fetal Programming -- (B) Thrifty Phenotype Hypothesis -- (C) Epigenetic Modification of Gene -- Conclusion -- References -- Chapter IV Dietary Magnesium and Metabolic Syndrome -- Abstract -- Introduction -- Dietary Intake of Magnesium -- Magnesium Intake and Systemic Low-Grade Inflammatory Syndrome -- Magnesium Intake and Metabolic Syndrome -- Conclusion -- References -- Chapter V Relation of Vitamin D, Calcium, and Magnesium to the Risk of Type 2 Diabetes Mellitus -- Abstract -- I. Introduction -- II. A Brief Overview of the Vitamin D Endocrine System -- A. Overview -- B. Interaction with Calcium and Phosphorous.

C. Interaction with Calciotropic Hormones -- D. Interaction with Magnesium -- III. Vitamin D Status -- A. Vitamin D Status and the Elderly -- B. Vitamin D Status and Obesity -- C. Vitamin D Status and Ethnicity -- D. Health Effects of Low Vitamin D Status -- IV. Vitamin D and Type 2 Diabetes -- A. Animal Evidence -- B. Evidence from Studies in Humans -- Cross-Sectional Evidence -- Prospective Cohort Evidence -- Clinical Intervention Trials -- V. Potential Biological Mechanisms -- A. Insulin Secretion -- Independent Effects of Vitamin D -- Joint Effects of Vitamin D and Calcium -- Joint Effects of Vitamin D and Magnesium -- B. Insulin Resistance -- Independent Effects of Vitamin D -- Joint Effects of Vitamin D and Calcium -- Joint Effects of Vitamin D and Magnesium -- VI. Genetic Variants -- A. Vitamin D Receptor (VDR) Polymorphisms -- B. Magnesium and Calcium Homeostasis-Related Genetic Variants -- Conclusion -- References -- Chapter VI Enhancement of Magnesium Content in Plants by Exploiting Ionomics and Transcriptomics -- Abstract -- 1. Magnesium in Plant Physiology -- 1.1. Incidence of Magnesium Deficiency in Forestry and Agriculture -- 1.2. Involvement of Magnesium in Assimilates Partitioning -- 2. Magnesium in Human Nutrition -- 2.1. Incidence of Magnesium Deficiency in Human Body -- 2.2. Research on Magnesium Homeostasis: Insights on Mechanisms in Regulating Magnesium Content in Edible Plants -- 2.2.1. Exploiting Magnesium Content Variation Induced by Mutagenesis or Genetic Engineering in Plants -- Arabidopsis Mutants Which Contain Abnormal Levels of Mg -- Genetic Engineering of Mg Transporters -- 2.2.2. Exploiting Natural Magnesium Content Variation in Arabidopsis Populations -- 2.2.3. Identifying Transcriptome Changes in Early and Late Signalling of Mg Deficiency -- 2.2.4. Transferring the Benefits from Arabidopsis Research to Brassica.

Acknowledgments -- References -- Chapter VII A Role for Magnesium in the Regulation of Ruminal Sodium Transport -- Abstract -- Introduction -- The Ruminant Species: Adaptation to a Roughage Diet -- Saliva -- The Rumen -- Histology and Organogenesis -- Ruminal Osmoregulation -- The Role of the Rumen in the Potassium Balance of Ruminants -- Transport of Sodium and Chloride across the Rumen -- Electrogenic Na+ Conductance in the Rumen -- Mg2+ Gating of Ion Channels -- Absorption of Magnesium -- Ruminal transport of potassium -- A Role for Magnesium in Ruminal Osmoregulation -- Conclusion -- References -- Chapter VIII Zinc, Copper, Manganese and Magnesium in Liver Cirrhosis -- Abstract -- 1. Liver Cirrhosis -- 1.1. Epidemiology -- 1.2. Definition -- 1.3. Etiology -- 1.4. Alcoholic Liver Disease -- 1.5. Pathogenesis of Alcoholic Liver Disease -- 1.6. Clinical Manifestations of Liver Cirrhosis -- 1.7. Treatment of Patients with Liver Cirrhosis -- 2. Trace Elements -- 2.1. Definition -- 2.2. Zinc, Copper, Manganese and Magnesium in Liver Cirrhosis -- 2.2.1. Zinc -- 2.2.2. Copper -- 2.2.3. Manganese -- 2.2.4. Magnesium -- 3. Material and Methods -- 3.1. Subjects -- 3.2. Methods -- 4. Results -- 5. Discussion -- 6. Conclusion -- References -- Index -- Blank Page.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.